Venomyx Therapeutics
Early Stage
EpiPen for snakebites: the antivenom of tomorrow!
Overview
Raised: $297,421
Total Commitments ($USD)
Platform
Wefunder
Start Date
03/14/2019
Close Date
07/03/2019
Min. Goal
$50,000
Max. Goal
$1,070,000
Min. Investment
$100
Security Type
SAFE
SEC Filing Type
RegCF
Valuation Cap
$4,000,000
Discount
15%
Rolling Commitments ($USD)
Status
Funded
Reporting Date
07/31/2019
Days Remaining
Funded
% of Min. Goal
595%
% of Max. Goal
28%
Likelihood of Max
Funded
Avg. Daily Raise
$2,679
# of Investors
506
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2015
Industry
Healthcare & Pharmaceuticals
Tech Sector
Location
La Jolla, California
Venomyx Therapeutics, with a valuation cap of $5 million, is raising crowdfunding on WeFunder. The company is developing Vipax, the world’s first broad-spectrum antivenom for snakebites. The product is ten times more effective than traditional antivenoms and much cheaper. Venomyx Therapeutics was founded by Daniel Dempsey and Deepankar Roy. The proceeds of the current crowdfunding round, with a minimum raise of $50,000, will be used to complete the preclinical trials, file an application to the FDA, and finish the research. Venomyx Therapeutics is expected to be a revolution while using biotechnology, and not animals, for the production of antivenom.
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Wall Street has Morningstar, S&P, and Bloomberg
The equity crowdfunding market has KingsCrowd.
Are you the founder of Venomyx Therapeutics? Create your account today to claim this raise page.